<DOC>
	<DOCNO>NCT00748553</DOCNO>
	<brief_summary>The purpose clinical trial test whether treatment patient advance metastatic solid tumor breast cancer Abraxane plus Vidaza safe result good tumor response . All patient enrol study receive treatment Abraxane Vidaza . Safety assess adverse event , laboratory result performance status . Tumor response measure RECIST criterion .</brief_summary>
	<brief_title>A Phase I/II Clinical Trial Vidaza With Abraxane Treatment Patients With Advanced Metastatic Solid Tumors Breast Cancer</brief_title>
	<detailed_description>The phase I part study enroll patient advance metastatic solid tumor fail least one previous treatment . The purpose phase I part ass safety investigational treatment select recommend phase II dose-regimen . The phase II part study enroll patient advance metastatic HER2-negative breast cancer receive treatment metastatic disease . The purpose phase II part study ass safety efficacy investigational treatment breast cancer . The study doctor determine phase patient enrol .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . For phase I , solid tumor , include lymphoma , progress stable best response least one previous therapy evaluable . 2 . For phase II , pathologically confirm breast cancer , measurable disease , prior treatment recurrent metastatic breast cancer . 3 . Her2/neu negative ( Phase II ) 4 . Negative pregnancy test female subject 5 . Women childbearing potential advise avoid become pregnant men advise father child receive treatment azacitidine nabpaclitaxel . investigator . 6 . Male female phase I female phase II , &gt; 19 year age race . 1 . Major surgery , radiotherapy , chemotherapy investigational agent within 4 week treatment day 1 2 . Known brain metastasis 3 . Prior taxanes ( except adjuvant therapy 6 month prior treatment day 1 ) ( phase II ) 4 . Active infection require antibiotic therapy 5 . History allergy hypersensitivity nabpaclitaxel , albumin taxane 6 . Grade 2 great motor sensory neuropathy 7 . Prior cytotoxic chemotherapy recurrent metastatic breast cancer ( phase II portion ) 8 . Uncontrolled hypertension , arrhythmia , congestive heart failure angina . Patients myocardial infarction cardiac surgery least 6 month event free active symptom . 9 . Known suspected hypersensitivity azacitidine mannitol 10 . Pregnant breast feed 11 . Patients advance malignant hepatic tumor 12 . Malignancy breast carcinoma ( phase II ) 13 . Known HIV infection chronic hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>